New Zealand markets close in 1 hour 48 minutes

Haleon plc (HLN.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
331.00-8.50 (-2.50%)
At close: 04:53PM BST
Full screen
Previous close339.50
Open0.00
Bid0.00 x N/A
Ask0.00 x N/A
Day's range0.00 - 0.00
52-week range
Volume2,617,548
Avg. volume26,086,705
Market cap30.228B
Beta (5Y monthly)N/A
PE ratio (TTM)30.09
EPS (TTM)0.11
Earnings date01 Aug 2024 - 15 Aug 2024
Forward dividend & yield0.06 (1.77%)
Ex-dividend date14 Mar 2024
1y target est363.53
  • Reuters

    UPDATE 2-Sensodyne-maker Haleon posts tepid sales as demand for some products cool off

    Consumer healthcare company Haleon reported first-quarter revenue slightly below market estimates on Wednesday, as volumes declined due to retailer destocking in U.S. and cooling demand for some of its medicines after a surge last year. The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth.

  • Reuters

    Sensodyne-maker Haleon posts tepid sales as demand for some products cool off

    The maker of popular household products such as Sensodyne toothpaste and pain-reliever Panadol, had earlier said that the first three months of 2024 would be impacted by a softer cold and flu season and a slowdown in painkiller Advil's sales in Canada, following a surge in demand last year. Demand for medicines such as Contac and Fenbid, which benefited from pent-up demand in China last year after lockdown restrictions were lifted, have also cooled, impacting Haleon's quarterly sales growth. On a reported basis, revenue was down 2.2% on last year.

  • PA Media: Money

    Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

    The consumer healthcare group is aiming to close the site on a phased basis over the next two years.